Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.

Publication Type:

Journal Article


Cancer, Volume 112, Issue 12, p.2789-95 (2008)


2008, Alcohol Oxidoreductases, Anthracyclines, Case-Control Studies, Child, Clinical Research Division, Female, Heart Failure, Humans, Male, NAD(P)H Dehydrogenase (Quinone), Neoplasms, Polymorphism, Genetic, Public Health Sciences Division, Risk Factors, Survivors


Exposure to anthracyclines as part of cancer therapy has been associated with the development of congestive heart failure (CHF). The potential role of genetic risk factors in anthracycline-related CHF remains to be defined. Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene CBR3) had an impact on the risk of anthracycline-related CHF.